SCHEMBL6492175

SCHEMBL6492175

O=S(=O)(Cc1ccccc1)NS(=O)(=O)Cc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.68
CA2 P00918 2/20 0.68
MMP1 P03956 1/20 0.68
MMP2 P08253 1/20 0.68
MMP9 P14780 1/20 0.68
MMP8 P22894 1/20 0.68
MMP13 P45452 1/20 0.68
FAAH O00519 1/20 0.56
PRSS1 P07477 1/20 0.56
PRSS2 P07478 1/20 0.56
ELANE P08246 1/20 0.56
PRTN3 P24158 1/20 0.56
PRSS3 P35030 1/20 0.56
CA5A P35218 1/20 0.56
CA9 Q16790 1/20 0.56
KMT2A Q03164 2/20 0.55
PGR P06401 1/20 0.52
ALDH1A1 P00352 2/20 0.50
HPGD P15428 2/20 0.50
AR P10275 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24361302 0.87 CA1 (0.59) CA1CA2MMP1MMP2MMP9
SCHEMBL24360900 0.85 CA1 (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL9006011 0.83 CA1 (0.65) CA1CA2MMP1MMP2MMP9
SCHEMBL21763639 0.83 CA1 (0.65) CA1CA2MMP1MMP2MMP9
SCHEMBL465380 0.83 CA1 (0.65) CA1CA2MMP1MMP2MMP9
SCHEMBL4301369 0.82 CA1 (0.53) CA1CA2MMP1MMP2MMP9
SCHEMBL10656290 0.81 CA1 (1.00) CA1CA2MMP1MMP2MMP9
SCHEMBL12068211 0.81 CA1 (0.63) CA1CA2MMP1MMP2MMP9
SCHEMBL4678467 0.81 CA1 (0.63) CA1CA2MMP1MMP2MMP9
SCHEMBL13325 0.81 CA1 (0.63) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US claimed
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
EP-1198505-B1 CARBONATE POLYMER COMPOSITIONS STABILIZED AGAINST DISCOLORATION AND PHYSICAL PROPERTY DETERIORATION DURING STERILIZATION BY IONIZING RADIATION DOW GLOBAL TECHNOLOGIES INC (US) 2004-01-07 EP disclosed
EP-1198505-A1 CARBONATE POLYMER COMPOSITIONS STABILIZED AGAINST DISCOLORATION AND PHYSICAL PROPERTY DETERIORATION DURING STERILIZATION BY IONIZING RADIATION THE DOW CHEMICAL COMPANY (US) 2002-04-24 EP disclosed
US-6166116-A Carbonate polymer compositions stabilized against discoloration and physical property deterioration during sterilization by ionizing radiation THE DOW CHEMICAL COMPANY (US) 2000-12-26 US disclosed
WO-2000075223-A1 CARBONATE POLYMER COMPOSITIONS STABILIZED AGAINST DISCOLORATION AND PHYSICAL PROPERTY DETERIORATION DURING STERILIZATION BY IONIZING RADIATION THE DOW CHEMICAL COMPANY (US) 2000-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 CA1 4466/4885CA2 3850/4885MMP1 968/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 CA1 2761/4885CA2 1990/4885MMP1 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.